

**Contact:**  
**Tracy Everly**  
**SDI**  
**267.685.4387**  
**teverly@sdihealth.com**

**Jack Loughran**  
**Buchanan Public Relations**  
**610.649.9292**  
**jack@buchananpr.com**

**FOR IMMEDIATE RELEASE**

**SDI REPORTS: ANTIVIRAL PRESCRIPTIONS INCREASE 36% IN 1 WEEK**  
Volume of prescriptions for flu therapies higher than during last season's peak

PLYMOUTH MEETING, Pa. – Oct. 22, 2009 – [SDI](#)'s Vector One®: National shows that for the week ending Oct. 16, the number of antiviral prescriptions dispensed at retail pharmacies was 36% higher than the prior week.

Over 502,000 prescriptions were filled for Tamiflu in the week ending Oct. 16, up 37% from just over 367,000 the week before. Prescriptions for Relenza increased 24%, from approximately 6,600 in the week ending Oct. 9 to approximately 8,200 for the week ending Oct. 16.

Antiviral prescriptions have increased each week since the week ending Aug. 21.

At 510,110, the volume of antiviral prescriptions last week is 88% higher than at the highest point last season, during the week ending May 1, when it reached 271,169.

Vector One®: National (VONA) is SDI's national-level prescription and patient tracking service. VONA provides a comprehensive overview of the national performance of all prescription drugs dispensed by retail pharmacies. Through agreements with data providers, SDI collects a robust sample of retail prescriptions dispensed and projects the activity through methods that stratify by geography, pay type, and class of trade.

VONA offers the fastest weekly projections available in the industry.

**About [SDI](#)**

SDI is a leading healthcare market insight and analytics firm. It provides the industry's most comprehensive de-identified patient-level data to pharmaceutical, biotech, and medical device companies, enabling them to better understand the healthcare market. SDI also serves the government and the financial services, media, and consumer packaged goods industries. Founded in 1982, SDI counts the world's top 50 pharmaceutical and biotech firms as its clients.